Martin Auster Recent News
Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal
Credit Suisse Joins Consensus To Prescribe Sarepta
Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade
United Therapeutics Has Limited Downside Below $95 Level, Credit Suisse Says In Upgrade
Credit Suisse Slashes Edge Therapeutics Price Target By 94%, Downgrades Stock After Failed Trial
The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse
Alexion's New CFO Continues To Shore Up Investor Concerns
Analyst: With This Much Pessimism Priced In, Alexion Begins To Look Attractive